ACTIVE_NOT_RECRUITING

Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

MOMENTOUS is a multi-center, randomized study to prospectively evaluate the performance of an ECG-based AI device to predict whether participants with interstitial lung disease (ILD) are at high risk of undiagnosed pulmonary hypertension.

Official Title

MOMENTOUS Study (iMpact Of an Ecg ai ModEl oN The Diagnosis Of pUlmonary hypertenSion)

Quick Facts

Study Start:2025-07-23
Study Completion:2028-07
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:ACTIVE_NOT_RECRUITING

Study ID

NCT06911632

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * 18 years or older at the time of consent
  2. * A known diagnosis of interstitial lung disease
  3. * Willing and able to provide informed consent and undergo all study-specific procedures, including echo and RHC, if required
  1. * A known diagnosis of pulmonary hypertension (including patients prescribed a therapy specifically for pulmonary arterial hypertension (PAH))
  2. * A RHC was completed within the previous 1 year or ordered and not yet completed at the time of consent
  3. * LV ejection fraction ≤ 40% on most recent echo or cardiac MRI, if available
  4. * Unclassifiable Tempus PH ECG risk result after up to 2 ECG acquisitions
  5. * A contraindication to RHC exists (for example, mechanical right heart valve)
  6. * Physician decision that if a patient is directed to RHC by the study protocol, the potential risks of RHC outweigh the potential benefits
  7. * There is a severe concomitant illness limiting life expectancy to less than 6 months (at the discretion of the investigator)
  8. * There is a medical or social factor that makes the patient a poor candidate for the study and/or unlikely to be able to comply with the study protocol or complete study procedures (at the discretion of the investigator)

Contacts and Locations

Study Locations (Sites)

University of Alabama at Birmingham
Birmingham, Alabama, 35205
United States
Banner University Medical Center
Phoenix, Arizona, 84006
United States
Dignity Health - St. Joseph's Hospital and Medical Center-Norton Thoracic Institute
Phoenix, Arizona, 85013
United States
National Jewish Health
Denver, Colorado, 80206
United States
AdventHealth Orlando
Orlando, Florida, 32803
United States
Northwestern University
Chicago, Illinois, 60611
United States
University of Illinois Health
Chicago, Illinois, 60612
United States
Indiana University Health Methodist Hospital
Indianapolis, Indiana, 46202
United States
Community Health Network
Indianapolis, Indiana, 46237
United States
University of Kentucky
Lexington, Kentucky, 40536
United States
Louisiana State University Health Shreveport
Shreveport, Louisiana, 71102
United States
University of Michigan - Michigan Medicine
Ann Arbor, Michigan, 48109-5360
United States
University of Minnesota
Minneapolis, Minnesota, 55455
United States
CHI Health Creighton University Medical Center - Bergan Mercy
Omaha, Nebraska, 68124
United States
University of Buffalo
Buffalo, New York, 14203
United States
Southeastern Research Center
Winston-Salem, North Carolina, 27103
United States
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44121
United States
University of Oklahoma
Oklahoma City, Oklahoma, 73104
United States
Temple University of The Commonwealth System of Higher Education
Philadelphia, Pennsylvania, 19140
United States
Baylor University Medical Center
Dallas, Texas, 75246
United States
Baylor College of Medicine
Houston, Texas, 77030
United States
University of Utah
Salt Lake City, Utah, 84103
United States
West Virginia University Hospital
Morgantown, West Virginia, 26505
United States

Collaborators and Investigators

Sponsor: Tempus AI

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-07-23
Study Completion Date2028-07

Study Record Updates

Study Start Date2025-07-23
Study Completion Date2028-07

Terms related to this study

Keywords Provided by Researchers

  • Pulmonary Hypertension
  • Interstitial lung disease (ILD)

Additional Relevant MeSH Terms

  • Pulmonary Hypertension
  • Interstitial Lung Disease (ILD)